Shorter, gentler hormone therapy tested in prostate cancer fight
NCT ID NCT06111781
Summary
This study is testing if a shorter course of an oral hormone-blocking drug (Relugolix), given alongside a precise, high-dose radiation treatment (SBRT), works better than the radiation alone for men with a specific type of intermediate-risk prostate cancer. The goal is to see if this combination can better control the cancer while causing fewer long-term side effects like sexual dysfunction and fatigue that are common with longer hormone therapies. About 60 men will be randomly assigned to receive either the combination treatment or radiation by itself.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10017, United States
Contact
Contact Email: •••••@•••••
-
University of Washington
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.